stockportfolio.pro
Stocks / EMBC vs FULC
EMBC vs FULC
Embecta Corp. and Fulcrum Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Embecta Corp. (EMBC) | Fulcrum Therapeutics, Inc. (FULC) | |
|---|---|---|
| Market cap | $0.2B | $0.2B |
| Revenue (latest FY) | $1.08B | $0 |
| Net income (latest FY) | $95.40M | $-74.88M |
| Revenue growth (5y CAGR) | -0.1% | — |
| Net margin | 8.8% | — |
| Return on equity | -14.7% | -21.5% |
| P/E ratio | 1.7 | — |
| Dividend yield | 13.9% | — |
| Profitable years (of last 10) | 6 | 0 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open EMBC — free Open FULC — freeFrequently asked questions
Which is bigger, EMBC or FULC?
Fulcrum Therapeutics, Inc. is larger by market capitalization — $0.2B versus $0.2B.
Which grows faster, EMBC or FULC?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.